Hypofractionated Re-irradiation after Maximal Surgical Resection for Recurrent Glioblastoma: Therapeutic Adequacy and Its Prognosticators of Survival
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: To evaluate the adequacy of retreatment, including hypofractionated re-irradiation (HFReRT), after surgery for recurrentglioblastoma (GBM) and related prognosticators of outcomes. Materials and Methods: From 2011 to 2014, 25 consecutive patients with recurrent (n=17) or secondary (n=7) disease underwent maximal surgery and subsequent HFReRT after meeting the following conditions: 1) confirmation of recurrent or secondary GBM after salvage surgery; 2) Karnofsky performance score (KPS) ≥60; and 3) interval of ≥12 months between initial radiotherapy and HFReRT. HFReRT was delivered using a simultaneous integrated boost technique, with total dose of 45 Gy in 15 fractions to the gross tumor volume (GTV) and 37.5 Gy in 15 fractions to the clinical target volume. Results: During a median follow-up of 13 months, the median progression-free and overall survival (OS) were 13 and 16 months, respectively. A better KPS (p=0.026), no involvement of the eloquent area at recurrence (p=0.030), and a smaller GTV (p=0.005) were associated with better OS. Additionally, OS differed significantly between risk groups stratified by the National Institutes of Health Recurrent GBM Scale (low-risk vs. high-risk, p=0.025). Radiologically suspected radiation necrosis (RN) was observed in 16 patients (64%) at a median of 9 months after HFReRT, and 8 patients developed grade 3 RN requiring hospitalization. Conclusion: HFReRT after maximal surgery prolonged survival in selected patients with recurrent GBM, especially those with small-sized recurrences in non-eloquent areas and good performance.
Abstract
Purpose: To evaluate the adequacy of retreatment, including hypofractionated re-irradiation (HFReRT), after surgery for recurrentglioblastoma (GBM) and related prognosticators of outcomes. Materials and Methods: From 2011 to 2014, 25 consecutive patients with recurrent (n=17) or secondary (n=7) disease underwent maximal surgery and subsequent HFReRT after meeting the following conditions: 1) confirmation of recurrent or secondary GBM after salvage surgery; 2) Karnofsky performance score (KPS) ≥60; and 3) interval of ≥12 months between initial radiotherapy and HFReRT. HFReRT was delivered using a simultaneous integrated boost technique, with total dose of 45 Gy in 15 fractions to the gross tumor volume (GTV) and 37.5 Gy in 15 fractions to the clinical target volume. Results: During a median follow-up of 13 months, the median progression-free and overall survival (OS) were 13 and 16 months, respectively. A better KPS (p=0.026), no involvement of the eloquent area at recurrence (p=0.030), and a smaller GTV (p=0.005) were associated with better OS. Additionally, OS differed significantly between risk groups stratified by the National Institutes of Health Recurrent GBM Scale (low-risk vs. high-risk, p=0.025). Radiologically suspected radiation necrosis (RN) was observed in 16 patients (64%) at a median of 9 months after HFReRT, and 8 patients developed grade 3 RN requiring hospitalization. Conclusion: HFReRT after maximal surgery prolonged survival in selected patients with recurrent GBM, especially those with small-sized recurrences in non-eloquent areas and good performance.
참고문헌 (29)
- Stupp R, "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma", N Engl J Med, 352, pp.987~996 (2005)[DOI]
- Milano MT, "Patterns and timing of recurrence after temozolomidebased chemoradiation for glioblastoma", Int J Radiat Oncol Biol Phys, 78, pp.1147~1155 (2010)[DOI]
- Stupp R, "Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial", Lancet Oncol, 10, pp.459~466 (2009)[DOI]
- Brandes AA, "Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status", J Clin Oncol, 27, pp.1275~1279 (2009)[DOI]
- Sherriff J, "Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide", Br J Radiol, 86, pp.20120414~ (2013)[DOI]
- Taunk NK, "External beam re-irradiation, combination chemoradiotherapy, and particle therapy for the treatment of recurrent glioblastoma", Expert Rev Anticancer Ther, 16, pp.347~358 (2016)[DOI]
- Montemurro N, "Second surgery for recurrent glioblastoma: a concise overview of the current literature", Clin Neurol Neurosurg, 142, pp.60~64 (2016)[DOI]
- Barbagallo GM, "'Recurrent' glioblastoma multiforme, when should we reoperate?", Br J Neurosurg, 22, pp.452~455 (2008)[DOI]
- Park JK, "Scale to predict survival after surgery for recurrent glioblastoma multiforme", J Clin Oncol, 28, pp.3838~3843 (2010)[DOI]
- Park CK, "A practical scoring system to determine whether to proceed with surgical resection in recurrent glioblastoma", Neuro Oncol, 15, pp.1096~1101 (2013)[DOI]
- Shi W, "Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas", J Neurooncol, 127, pp.535~539 (2016)[DOI]
- Wuthrick EJ, "A pilot study of hypofractionated stereotactic radiation therapy and sunitinib in previously irradiated patients with recurrent high-grade glioma", Int J Radiat Oncol Biol Phys, 90, pp.369~375 (2014)[DOI]
- Fogh SE, "Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas", J Clin Oncol, 28, pp.3048~3053 (2010)[DOI]
- Nieder C, "Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma", Am J Clin Oncol, 31, pp.300~305 (2008)[DOI]
- Kong DS, "Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas", Cancer, 112, pp.2046~2051 (2008)[DOI]
- 이정심, "Re-Irradiation for Recurrent Gliomas: Treatment Outcomes and Prognostic Factors", Yonsei Medical Journal, 57(4), pp.824~830 (2016), 연세대학교의과대학[DOI]
- Vogelbaum MA, "The benefit of surgical resection in recurrent glioblastoma", Neuro Oncol, 18, pp.462~463 (2016)[DOI]
- Scorsetti M, "Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma", BMC Cancer, 15, pp.486~ (2015)[DOI]
- Na A, "Cerebral radiation necrosis", Asia Pac J Clin Oncol, 10, pp.11~21 (2014)
- Minniti G, "Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma", J Neurooncol, 103, pp.683~691 (2011)[DOI]
- Amelio D, "Radiation therapy for the treatment of recurrent glioblastoma: an overview", Cancers (Basel), 4, pp.257~280 (2012)[DOI]
- Combs SE, "Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution", J Clin Oncol, 23, pp.8863~8869 (2005)[DOI]
- Grosu AL, "Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)", CT, Int J Radiat Oncol Biol Phys, pp.2005, 63[DOI]
- Suchorska B, "Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial", Neuro Oncol, 18, pp.549~556 (2016)[DOI]
- Grabowski MM, "Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma", J Neurosurg, 121, pp.1115~1123 (2014)[DOI]
- Sminia P, "External beam radiotherapy of recurrent glioma: radiation tolerance of the human brain", Cancers (Basel), 4, pp.379~399 (2012)[DOI]
- Lawrence YR, "Radiation dose-volume effects in the brain", Int J Radiat Oncol Biol Phys, 76(3 Suppl), pp.S20~S27 (2010)[DOI]
- Mayer R, "Reirradiation tolerance of the human brain", Int J Radiat Oncol Biol Phys, 70, pp.1350~1360 (2008)[DOI]
- Flechl B, "The caregivers' perspective on the end-of-life phase of glioblastoma patients", J Neurooncol, 112, pp.403~411 (2013)[DOI]